(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[6-(2-methylphenyl)pyridin-1-ium-3-yl]propanoic acid;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[6-(2-methylphenyl)pyridin-1-ium-3-yl]propanoic acid;chloride
• 化学式: C30H27ClN2O4
• 分子量: 515.0
• InChiKey: MRAILQIBRRTTAY-JCOPYZAKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.01
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  89.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(6-(o-tolyl)pyridin-3-yl)propanoate 、 无水氯化钙 在 乙醚 、 hydrochloric acid diethyl ether 作用下， 以 三氟乙酸 为溶剂， 反应 2.0h， 以to give the desired compound as a white powder, 1.65 g, 100% yield的产率得到(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[6-(2-methylphenyl)pyridin-1-ium-3-yl]propanoic acid;chloride
  参考文献：
  名称：

  N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS

  摘要：

  本文所述主题提供了新颖的人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于天然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或疾病。所述化合物包括化学修饰的肽，可以刺激2型糖尿病患者的胰岛素分泌，但也产生其他有益的胰岛素促分泌反应。这些合成肽GLP-1受体调节剂表现出对蛋白酶解的稳定性增加，使它们成为口服或静脉注射的理想治疗候选药物。所披露和声称的肽显示出理想的药代动力学特性和糖尿病疗效模型的理想效力。

  公开号：

  US20080045461A1

文献信息

• Sustained release GLP-1 receptor modulators
  申请人：Qian Feng

  公开号：US20070099835A1

  公开（公告）日：2007-05-03

  The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.

  本发明提供了一种新型药物组合物，包括一种人类胰高血糖素样肽-1（GLP-1）受体调节剂作为活性成分，并以缓释制剂的形式进行。
• Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
  申请人：Ewing R. William

  公开号：US20060287242A1

  公开（公告）日：2006-12-21

  The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

  本发明提供了新型人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于自然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或障碍。此外，本发明提供了新型的化学修饰肽，不仅刺激2型糖尿病患者的胰岛素分泌，而且产生其他有益的胰岛素促进反应。这些合成肽GLP-1受体调节剂具有增强的蛋白酶水解稳定性，使它们成为口服或静脉注射的理想治疗候选药物。本发明的肽具有理想的药代动力学特性和在糖尿病疗效模型中的理想效力。
• HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Ewing William R.

  公开号：US20080242593A1

  公开（公告）日：2008-10-02

  The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

  本发明提供了新型的人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于天然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或障碍。此外，本发明提供了新型的化学修饰肽，不仅能刺激2型糖尿病患者的胰岛素分泌，还能产生其他有益的胰岛素促进反应。这些合成肽GLP-1受体调节剂具有较高的蛋白酶水解稳定性，使其成为口服或静脉注射的理想治疗候选药物。本发明的肽具有理想的药代动力学特性和糖尿病疗效模型的理想效力。
• Sustained release glp-1 receptor modulators
  申请人：Qian Feng

  公开号：US20100022457A1

  公开（公告）日：2010-01-28

  The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.

  本发明提供了一种新型药物组合物，其中包含一种人类胰高血糖素样肽-1（GLP-1）受体调节剂作为活性成分，以持续释放的形式进行制剂。
• N-terminally modified GLP-1 receptor modulators
  申请人：Ewing R. William

  公开号：US20070021346A1

  公开（公告）日：2007-01-25

  The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

  本文所描述的主题提供了一种新颖的人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于天然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或障碍。所描述的化合物包括化学修饰的肽，不仅能够刺激II型糖尿病患者的胰岛素分泌，还产生其他有益的胰岛素促进反应。这些合成肽GLP-1受体调节剂表现出对蛋白酶水解的稳定性增加，使它们成为口服或静脉注射的理想治疗候选药物。所披露和要求的肽具有理想的药代动力学特性和糖尿病疗效模型中的理想效力。